Coegin Pharma will provide a new generation of therapeutics treating serious medical conditions associated with chronic inflammatory disorders and specific cancers.
Avexxin has become Coegin Pharma
Avexxin changes the company name to Coegin Pharma.
Coegin Pharma is presenting at several conferences throughout the year, showcasing current progress and development status.
All of Avexxin’s small molecules are nanomolar potent drug candidates targeting chronic inflammatory disorders and cancers with high unmet need. The individual compounds represent a series of international drug discovery efforts conducted in collaboration with key leaders in the field
Coegin Pharma is a global leader in understanding the role of an intracellular target downstream of the classical therapeutic intervention of the pro-inflammatory cascade activated by NFkB. Coegin Pharma’s small molecules inhibits the group IVA cPLA2 enzyme, however still allowing the cell to function at the physiological level.
Avexxin presents the newest paper published in a scientific journal with the title “A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.”